Daily activities are limited by knee osteoarthritis and correlate with perceived disability and quality of life

This study aimed to evaluate the effects of treatment with Peruíbe Black Mud (PBM) on the clinical parameters and quality of life of patients with knee osteoarthritis and to compare the effects of PBM samples simply matured in seawater and PBM sterilized by gamma radiation. A controlled, double-blind trial was conducted with 41 patients divided into two treatment groups composed of 20 and 21 patients: one group was treated with matured PBM and the other with sterilized PBM. Evaluations were done using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Medical Outcomes Study Short Form 36 (SF-36) questionnaires, the Kellgren and Lawrence (KL) radiographic scale, and the quantification of the serum levels of inflammatory biomarkers. An improvement in pain, physical functions, and quality of life was observed in all of the patients who underwent treatment with both simply matured and sterilized PBM. Nine patients showed remission in the KL radiographic scale, but no statistically significant differences were observed in the serum levels of inflammatory mediators before or after treatment. Peruíbe Black Mud proves to be a useful tool as an adjuvant treatment for knee osteoarthritis (OA), as shown by the results of the WOMAC and SF-36 questionnaires and by the remission of the radiographic grade of some patients on the Kellgren and Lawrence scale.

Download Full-text

Validation of the Impact Index: can we measure disease effects on quality of life in patients with hip and knee osteoarthritis?

Quality of Life Research ◽

10.1007/s11136-020-02728-7 ◽

2021 ◽

Author(s):

K. D. Valentine ◽

S. Brodney ◽

Ha Vo ◽

Karen Sepucha ◽

Floyd J. Fowler ◽

...

Keyword(s):

Quality Of Life ◽

Knee Osteoarthritis ◽

Impact Index ◽

The Impact

Download Full-text

Phonophoresis of semisolid formulation of Zingiber officinale Roscoe hydroalcoholic extract improves quality of life in patients with moderate knee osteoarthritis: A randomized clinical trial

Journal of Herbal Medicine ◽

10.1016/j.hermed.2021.100464 ◽

2021 ◽

pp. 100464

Author(s):

Amin Kordi Yoosefinejad ◽

Mohammad Mehdi Zarshenas ◽

Javad Sadeghi Mazidi ◽

Mozhde Tahmasbi

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Knee Osteoarthritis ◽

Randomized Clinical Trial ◽

Zingiber Officinale ◽

Hydroalcoholic Extract ◽

Zingiber Officinale Roscoe

Download Full-text

Comparison of Blood Flow Restriction Training versus Non-Occlusive Training in Patients with Anterior Cruciate Ligament Reconstruction or Knee Osteoarthritis: A Systematic Review

Journal of Clinical Medicine ◽

10.3390/jcm10010068 ◽

2020 ◽

Vol 10 (1) ◽

pp. 68

Author(s):

Cristina Bobes Álvarez ◽

Paloma Issa-Khozouz Santamaría ◽

Rubén Fernández-Matías ◽

Daniel Pecos-Martín ◽

Alexander Achalandabaso-Ochoa ◽

...

Keyword(s):

Quality Of Life ◽

Systematic Review ◽

Blood Flow ◽

Anterior Cruciate Ligament ◽

Knee Osteoarthritis ◽

Acl Reconstruction ◽

Cruciate Ligament ◽

Flow Restriction ◽

Anterior Cruciate

Patients undergoing anterior cruciate ligament (ACL) reconstruction and patients suffering from knee osteoarthritis (KOA) have been shown to have quadriceps muscle weakness and/or atrophy in common. The physiological mechanisms of blood flow restriction (BFR) training could facilitate muscle hypertrophy. The purpose of this systematic review is to investigate the effects of BFR training on quadriceps cross-sectional area (CSA), pain perception, function and quality of life on these patients compared to a non-BFR training. A literature research was performed using Web of Science, PEDro, Scopus, MEDLINE, Dialnet, CINAHL and The Cochrane Library databases. The main inclusion criteria were that papers were English or Spanish language reports of randomized controlled trials involving patients with ACL reconstruction or suffering from KOA. The initial research identified 159 publications from all databases; 10 articles were finally included. The search was conducted from April to June 2020. Four of these studies found a significant improvement in strength. A significant increase in CSA was found in two studies. Pain significantly improved in four studies and only one study showed a significant improvement in functionality/quality of life. Low-load training with BFR may be an effective option treatment for increasing quadriceps strength and CSA, but more research is needed.

Download Full-text

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286421993999 ◽

2021 ◽

Vol 14 ◽

pp. 175628642199399 ◽

Cited By ~ 1

Author(s):

Annette Wundes ◽

Sibyl Wray ◽

Ralf Gold ◽

Barry A. Singer ◽

Elzbieta Jasinska ◽

...

Keyword(s):

Quality Of Life ◽

Medication Use ◽

Dimethyl Fumarate ◽

Daily Activities ◽

Phase Iii ◽

Symptomatic Medication ◽

Gi Symptoms ◽

Symptom Intensity ◽

The Impact

Background: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability versus dimethyl fumarate (DMF) with fewer days of Individual Gastrointestinal Symptom and Impact Scale (IGISIS) scores ⩾2, GI adverse events (AEs), and treatment discontinuations due to GI AEs. Our aim was to evaluate the impact of GI tolerability events on quality of life (QoL) for patients with relapsing–remitting MS who received DRF or DMF in EVOLVE-MS-2. Methods: A post hoc analysis was conducted in patients who were enrolled in the randomized, blinded, 5-week, EVOLVE-MS-2 [ClinicalTrials.gov identifier: NCT03093324] study of DRF versus DMF. Patients completed daily IGISIS and Global GISIS (GGISIS) eDiary questionnaires to assess GI symptom intensity and interference with daily activities and work. Results: In total, 504 patients (DRF, n = 253; DMF, n = 251) received study drug and 502 (DRF, n = 253; DMF, n = 249) completed at least one post-baseline questionnaire. With DRF, GI symptoms were less likely to interfere ‘quite a bit’ or ‘extremely’ with regular daily activities [IGISIS: DRF, 9.5% (24/253) versus DMF, 28.9% (72/249)] or work productivity [GGISIS: DRF, 6.1% (10/165) versus DMF, 11.3% (18/159)]. DRF-treated patients had fewer days with ⩾1 h of missed work (DRF, 43 days, n = 20 versus DMF, 88 days, n = 26). DMF-treated patients reported highest GI symptom severity and missed work at week 2–3 shortly after completing the titration period, which coincided with the majority of GI-related treatment discontinuations [58.3% (7/12)]. GI tolerability AEs [DRF, 34.8% (88/253); DMF, 48.2% (121/251)], concomitant symptomatic medication use [DRF, 19.3% (17/88) versus DMF, 30.6% (37/121)], and GI-related discontinuations (DRF, 0.8% versus DMF, 4.8%) were lower with DRF versus DMF. Conclusions: The improved GI tolerability with DRF translated into clinically meaningful benefits to QoL, as patients experienced less impact on daily life and work and required less concomitant symptomatic medication use. Trial registration: [ClinicalTrials.gov identifier: NCT03093324]

Download Full-text